Skip to content

Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host

Colorectal Neoplasms | Colorectal Cancer | Breast Cancer | Breast Neoplasms | Ovarian Cancer | Ovarian Neoplasm

By obtaining clinical specimens from participants with triple negative breast cancer (TNBC), colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor types to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with personalized cancer treatment options

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

1. Age \> 18 years.
2. Patient diagnosis must be categorized as either (I) OR (II) OR (III) OR (IV):

(I) Histologically confirmed Triple Negative Breast Cancer by Institutional and American Society of Clinical Oncology (ASCO)/Cancer of American Pathologists (CAP) guidelines, either:
* Stage IV (metastatic) disease that has not been treated with systemic therapy in the metastatic setting or
* Stage I to III (non-metastatic) with residual mass by clinical exam and/or breast imaging following anthracycline + taxane-containing neoadjuvant chemotherapy

OR

(II) Histologically-confirmed Stage IV colorectal cancer treated with ≤ 1 line of systemic therapy in the metastatic setting, either:
* Undergoing surgical resection of liver metastases or
* With metastatic lesions amenable to biopsy

OR

(III) Histologically-confirmed advanced High Grade Serous Ovarian Cancer, either:
* Recurrent disease with a life expectancy of at least 12 months or
* Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence

OR

(IV) Histologically confirmed solid tumor not meeting criteria for (I), (II) or (III) above, for which evaluation of investigational therapies is of particular interest or where clinical need exists, at the discretion of the PI
3. Disease amenable to biopsy or surgery for tissue procurement
4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
5. Willingness and ability of patient to provide signed voluntary informed consent.

Exclusion Criteria:

1. Clinically significant hepatic, renal, cardiac or other organ dysfunction likely to limit participation in clinical trials.
2. Known brain metastasis
3. Any condition that could interfere with a patient's ability to provide informed consent such as dementia or severe cognitive impairment.
4. Any contraindication to undergoing a biopsy procedure.

Study Location

Princess Margaret Cancer Centre
Princess Margaret Cancer Centre
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Elizabeth Shah

[email protected]
416-946-4501
Study Sponsored By
University Health Network, Toronto
Participants Required
More Information
Study ID: NCT02732860